Long-term protection of mice against Leishmania major with a synthetic peptide vaccine

Vaccine

Volumn 17, Issue 11-12, 1999, Pages 1298-1300

  Spitzer, N ^a   Jardim, A ^a   Lippert, D ^a   Olafson, R W ^a  

^a UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Leishmaniasis; Peptide vaccine; Poloxamer 407

Indexed keywords

PEPTIDE; POLOXAMER; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LEISHMANIA MAJOR; LEISHMANIASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; VACCINATION; VIRUS STRAIN;

ANIMALS; FEMALE; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; METALLOENDOPEPTIDASES; MICE; MICE, INBRED BALB C; POLOXAMER; PROTOZOAN VACCINES; VACCINATION; VACCINES, SYNTHETIC;

EID: 0033577295     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00363-6     Document Type: Article

References (16)

1. Locksley R.M., Heinzel F.P., Sadick M.D., Holaday B.J., Gardner K.D. Murine cutaneous leishmaniasis: susceptibility correlates with differential expansion of helper T cell subsets. Ann Inst Pasteur Immunol. 77:1987;338-347.
2. Scott P., Natovitz P., Coffman R.L., Pearce E., Sher A. Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J Exp Med. 168:1988;1675-1684.
3. + T cells during initiation of infection. J Exp Med. 179:1994;447-456.
4. + T cells through IL-12 produced by Listeria-induced macrophages. Science. 260:1993;547-549.
5. Afonso L.C., Scharton T.M., Vieira L.Q., Wysocka M., Trinchieri G., Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science. 260:1994;235-237.
6. Scott P., Pearce E., Natovitz P., Sher A. Vaccination against cutaneous leishmaniasis in a murine model. II. Immunologic properties of protective and nonprotective subfractions of a soluble promastigote extract. J Immunol. 139:1987;3118-3125.
7. Russell D.G., Alexander J. Effective immunization against cutaneous Leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol. 14:1988;1274-1279.
8. Connell N.D., Medina-Acosta E., McMaster W.R., Bloom B.R., Russell D.G. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63. Proc Nat Acad Sci USA. 90:1993;11473-11477.
9. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., Seder R.A. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med. 186:1997;1137-1147.
10. Jardim A., Alexander J., Teh H.S., Ou D., Olafson R.W. Immunoprotective Leishmania major synthetic T cell epitopes. J Exp Med. 172:1990;645-648.
11. Yang D.M., Rogers M.V., Liew F.Y. Identification and characterization of host-protective T cell epitopes of a major surface glycoprotein (gp63) from Leishmania major. Immunology. 72:1991;3-9.
12. Wang Z.-E., Reiner S.L., Hatam F., Heinzel F.P., Bouvier J., Turck C., Locksley R.M. Targeted activation of CD8 cells and infection of β2-microglobulin-deficient mice fail to confirm a primary protective role for CD8 cells in experimental leishmaniasis. J Immunol. 151:1993;2077-2086.
13. Reed C. Pluronic block copolymers as immunological adjuvants. Ph.D. Thesis, University of Strathclyde, 1993.
14. Ten-Hagen T.L., Sulzer A.J., Kidd M.R., Lal A.A., Hunter R.L. Role of adjuvants in the modulation of antibody isotype, specificity and induction of protection by whole blood-stage Plasmodium yoelii vaccines. J Immunol. 151:1993;7077-7085.
15. Hunter RL. Nonionic block copolymers: new preparations and a review of the mechanism of action. In: Spriggs DR, Koff WC, editors. Topics in vaccine adjuvant research. Boca Raton: CRC Press, 1991. p. 89-97.
16. Brey RN. Vaccine design. The subunit approach. In: Powell MF, Newman MJ, editors. Pharmaceutical biotechnology, vol. 6. Plenum Press, 1995. p. 297-311.